auro laboratories ltd Directors report


Dear Members,

Your directors have great pleasure in presenting the 34th Annual Report together with the Audited Financial Statements of the Company for the financial year ended March 31, 2023.

1. RESULTS OF OUR OPERATIONS AND STATE OF AFFAIRS

Financial Highlights

The audited financial statements of the Company as on March 31, 2023 are prepared in accordance with the relevant applicable IND AS and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and provisions of the Companies Act, 2013 (“Act”).

[Amount in 000 except EPS]

Particulars

For the Year ended

March 31, 2023 March 31, 2022

Revenue from operation

5,28,942 5,08,658

Other Income

9,413 10,925

Total Income

5,38,355 5,19,583

Profit before Finance Cost, Depreciation, Tax

53,340 57,175

Less: Finance Cost

8,142 8,264

Less: Depreciation & Amortization expenses

10,742 10,172

Profit Before Tax

34,457 38,739

Provision for -- Current Tax

10,008 10,669

-- Deferred Tax

28 (376)

Net Profit After Tax

24,420 28,446

Other Comprehensive Income (Net of tax)

3,526 1,114

Total Comprehensive Income After Tax

27,946 29,560

Earing Per Share (Basic & Diluted)

3.92 4.56

Notes:

The above figures are extracted from the audited standalone and consolidated financial statements of the Company as per the Indian Accounting Standards (Ind AS). Equity shares are at par value of Rs.10 per share.

Overview of companys financial performance and state of affairs:

Gross revenue was Rs. 528942033, as against Rs. 508658006 in the previous year. Profit after tax declined to Rs. 24420105 against Profit of Rs. 28446807 in the previous year.

Projects and expansion plans

Your Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA by the end of FY 2024. The demand for Metformin HCL is expected to increase in the near future owing to expected growth rate of over 10% worldwide in Type 2 Diabetes disease.

Dividend

To consolidate the financial position of the Company, the Board does not propose any dividend for the year ended March 31, 2023.

Transfer to reserves

As permitted under the provisions of the Companies Act, 2013, the Board does not propose to transfer any amount to general reserve.

Insurance

All properties and insurable interests of the Company including building, plant and machinery and stocks have been fully insured.

Particulars of loans, guarantees or investments

Loans, guarantees and investments covered under Section 186 of the Companies Act, 2013 form part of the Notes to the financial statements provided in this Annual Report.

Particulars of contracts or arrangements made with related parties

Prior omnibus approval is obtained for related party transactions which are of repetitive nature and entered in the ordinary course of business and on an arms length basis. All related party transactions are placed before the Audit Committee for review and approval.

No material related party transactions were entered during the Financial Year by your Company. Accordingly, no disclosure is made in respect of related party transactions, as required under Section 134(3) (h) of the Act in Form AOC-2. Members may refer to note no. 23(vii) of the financial statements which sets out related party disclosures pursuant to INDAS-24.

Material changes and commitments affecting financial position between the end of the financial year and date of the report

There have been no material changes and commitments which affect the financial position of the Company that have occurred between the end of the financial year to which the financial statements relate and the date of this report.

Deposits

Your Company has not accepted any deposits from the public within the meaning of Chapter V of the Act and as such, no amount of principal or interest was outstanding as on the balance sheet date.

Insolvency and Bankruptcy Code, 2016

During the year under review, no application was made or any proceeding was pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016).

One time Settlement with Banks/Financial Institutions

During the year under review, no one time settlement was done with any of the Banks or Financial Institutions.

Subsidiaries, joint ventures & associate

The Company does not have any subsidiaries, joint ventures & associate companies. The Company is also not a subsidiary of any other company.

Change in nature of business

There were no changes in the nature of business of the Company during the financial year.

2. CAPITAL STRUCTURE OF THE COMPANY

Authorized Share Capital

The Authorized Share Capital of the Company as at March 31, 2023 was Rs.7,00,00,000/- (Rupees Seven Crores only) divided into 70,00,000 (Seventy Lakhs) Equity shares of 10/- each.

Issued, Subscribed & Paid-up share Capital

The Paid up Equity share Capital, as at March 31, 2023 was Rs.6,23,25,000/- (Rupees Six Crores Twenty-Three Lakhs Twenty-Five Thousand only) divided into 62,32,500 (Sixty-Two Lakhs Thirty- Two Thousand Five Hundred) Equity shares, having face value of Rs.10/- each fully paid up. There was no change in the paid-up share capital of the Company during the FY 2022-23.

During the year under review, the Company has not issued any shares with differential voting rights nor granted any stock neither options nor sweat equity.

3. CORPORATE GOVERNANCE

Composition of Board of Directors

As on March 31, 2023 the Board of Directors consists of Six (6) members. Besides the Chairman & Managing Director, who is an Executive Director, the Board comprises of Two (2) Executive Directors, Three (3) Independent Directors (including one Woman Director) as on March 31, 2023. The composition of the Board is in conformity with the Companies Act, 2013 and Listing Regulations enjoining specified combination of Executive and Non-Executive Directors with at least one Women Independent Director and not less than fifty per cent of the Board comprising of Independent Directors.

In the opinion of the Board, all our Independent Directors possess requisite qualifications, experience, expertise and hold high standards of integrity for the purpose of Rule 8(5)(iii)(a) of the Companies (Accounts) Rules, 2014. List of key skills, expertise and core competencies of the Board, including the Independent Directors, forms part of the corporate governance report annexed to this report.

Changes during the year:

During the financial year under review, the following persons were appointed/re-appointed with the approval of the shareholders at the Annual General Meeting:

Name

Designation Appointment/

Re-appointment

Effective

date

Resolution passed by

Mr. Sharat Deorah

(DIN:00230784)

Chairman & Managing Director Re-appointment April 1, 2022

Shareholders at the 32nd AGM held on August 31,

Mr. Siddhartha Deorah

(DIN:00230796)

Whole Time Director Re-appointment April 1, 2022
2021

Mr. Kiran Suresh Kulkarni

(DIN: 09175595)

Whole Time Director Re-appointment u/s 152(6) July 20, 2022 Shareholders at the 33rd AGM held on July 20, 2022

Retirement by Rotation

In accordance with the provisions of the Companies Act, 2013 and the Articles of Association of the Company, Mr. Siddhartha Deorah, Whole Time Director of the Company is liable to retire by rotation at the ensuing Annual General Meeting of the Company and being eligible, has offered himself for reappointment. The Board recommends his re-appointment.

More details about the Directors are either given in the Corporate Governance Report and in the Notice of the ensuing Annual General Meeting being sent to the shareholders along with the Annual Report.

Changes in Board post closure of financial year

Post the closure of financial year, the following changes occurred in the Board of Directors of the Company:

• Mr. Govardhan Das Agarwal (DIN: 00545428) has tendered hisr resignation from the position of Independent Director of the Company with effect from the close of business bours on August 23, 2023.

• The Board of Directors, on recommendation of the Nomination and Remuneration Committee, in their meeting dated August 23, 2023 considered and approved appointment of Mr. Vishal Kailashchandra Jhunjhunwala (DIN: 00359872) as an additional Non-Executive Independent Director of the Company for a term of 5(five) years. Matter for his appointment shall be placed as agenda item in the notice of ensuing Annual General Meeting for approval of shareholders.

Key Managerial Personnel

As on March 31, 2023, the following persons were the Key Managerial Personnel of the Company in accordance with the provisions of Section 2(51) read with Section 203 of the Act:

Name of Personnel

Designation

Mr. Sharat Deorah

Chairman and Managing Director

Mr. Siddhartha Deorah

Whole-time Director

Mr. Amit Mahipat Shah

Chief Financial Officer

Mrs. Sweta Agarwal

Company Secretary

During the year, Ms. Shanu Nag ceased to be the Company Secretary w.e.f May 30, 2022 on account of her resignation and Ms. Sweta Agarwal was appointed as the Company Secretary w.e.f May 31, 2022.

Declaration of Independence by Independent Directors & adherence to the Companys Code of Conduct for Independent Directors

All Independent Directors of the Company have given declarations that they meet the criteria of independence as laid down under Section 149(6) of the Act and Regulation 16(1) (b) of the SEBI (LODR) Regulations, 2015 (“Listing Regulations”). In the opinion of the Board, the Independent

Directors, fulfill the conditions of independence specified in Section 149(6) of the Act and Regulation 16(1) (b) of the Listing Regulations.

All Independent Directors have affirmed compliance to the code of conduct for independent directors as prescribed in Schedule IV to the Companies Act, 2013.

Directors responsibility statement

Pursuant to Section 134 (3) (c) of the Companies Act, 2013 the Directors confirm that:

(a) In the preparation of the Annual Accounts, the applicable accounting standards had been followed along with proper explanation relating to material departure, if any;

(b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) The Directors had prepared the annual accounts on a going concern basis;

(e) The Directors, had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively;

(f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Committees of the board

The Board has the following Committees:

a) Audit Committee

b) Nomination & Remuneration Committee

c) Stakeholders Relationship Committee and

The Board of Directors in their meeting held on May 30, 2022, resolved that in terms of the amended provisions of Section 135 (9) of the Companies Act, 2013, the CSR Committee be dissolved.

Further details of the Committees along with their composition, number of meetings and attendance at the meetings are provided in the Corporate Governance Report.

Audit Committee Recommendations

All recommendations of Audit Committee were approved by the Board of Directors during the year. Independent directors meeting:

Independent Directors met 1 (one) time during the year on February 13, 2023 and the meeting was attended by all Independent Directors. The disclosure under this heading forms part of the Corporate Governance report.

Performance evaluation of the board, its committees and directors

Pursuant to the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015 the company has implemented a system of evaluating performance of the Board of Directors and of its Committees and individual directors on the basis of evaluation criteria suggested by the Nomination

and Remuneration Committee and the SEBI (LODR) Regulations, 2015. Accordingly, the Board has carried out an evaluation of its performance after taking into consideration various performance related aspects of the Boards functioning, composition of the Board and its Committees, culture, execution and performance of specific duties, remuneration, obligations and governance. The performance evaluation of the Board as a whole, Chairperson and Non-Independent Directors was also carried out by the Independent Directors in their meeting held on February 13, 2023.

Similarly, the performance of various committees, individual Independent and Non-Independent Directors was evaluated by the entire Board of Directors (excluding the Director being evaluated) on various parameters like engagement, analysis, decision making, communication and interest of stakeholders.

The Board of Directors expressed its satisfaction with the performance of the Board, its committees and individual directors.

Familiarization program for independent directors

All new independent directors inducted into the Board attend an orientation program. The details of the training and familiarization program are provided in the corporate governance report. Further, at the time of the appointment of an independent director, the Company issues a formal letter of appointment outlining his / her role, function, duties and responsibilities.

In compliance with the requirements of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has formulated a policy to familiarize the Independent Directors with the Company and the details of Familiarization Program are provided in the Corporate Governance Report and also available at http://www.aurolabs.com/contact/Familiarization Programme/financial- year-2022-2023.pdf

Corporate Policies

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, mandates the formulation of certain policies for all listed companies. The corporate governance policies are available on the Companys website, at www.aurolabs.com under the head “Corporate Policies”. The policies are reviewed periodically by the Board and updated as needed. Key policies that have been adopted are as follows:

Name of Policy

Brief Description

Nomination and Remuneration Policy

The Companys policy on remuneration of Directors, Key Managerial Personnel & Senior Employees and other matters provided in Section 178(3) of the Companies Act, 2013 has been disclosed in the Corporate Governance Report, which is a part of this report.

Performance evaluation Policy

The Nomination & Remuneration Committee pursuant to Section 178(2) of the Companies Act, 2013 has devised a policy on performance evaluation of the Board as a whole, Committee of the Board and Directors of the Company.

Board diversity

The Company recognizes and embraces the importance of a diverse board in its success. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors.

Code of conduct

Your Company is committed to conducting its business in accordance with the applicable laws, rules and regulations and highest standards of business ethics.
In recognition thereof, the Board of Directors has implemented a Code of Conduct for adherence by the Directors (including Independent Directors), Senior Management Personnel and Employees of the Company. This will help in dealing with ethical issues and also foster a culture of accountability and integrity.

All the Board Members and Senior Management Personnel have confirmed compliance with the Code.

Insider Trading Regulations

Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time, the Company has formulated a Code of Conduct for Prevention of Insider Trading (“Insider Trading Code”), a Code of Practices and Procedures for fair disclosure of Unpublished Price Sensitive Information (“UPSI”) and a policy & procedure for enquiry in case of leak/suspected leak of Unpublished Price Sensitive Information (“UPSI”).

Related party transactions

This policy deals with the review and approval of related party transactions.

Vigil mechanism / whistle blower policy

The Company has adopted a Whistle Blower Policy to provide a formal mechanism to the Directors and Employees to report their concerns about unethical behaviour, actual or suspected fraud or violation of the Companys Code of Conduct or Ethics Policy. The policy provides for adequate safeguards against victimization of employees who avail of the mechanism and also provides for direct access to the Chairperson of the Audit Committee. It is affirmed that no personnel of the Company has been denied access to the Audit Committee.

Annual Return

Pursuant to Section 92(3) and Section 134(3) (a) of the Companies Act, 2013, the Company has placed a copy of the Annual Return as at March 31, 2023 on its website at www.aurolabs.com at http://www.aurolabs.com/contact/Corporate%20Announcements/Corporate%20Announcement 20 23-2024/draft-mgt7 for-fy-2022-23.pdf

Corporate Governance and Management Discussion & Analysis Reports

The Company adheres to the requirements set out by the Securities and Exchange Board of Indias Corporate Governance practices and has implemented all the stipulations prescribed. The Company has implemented several best corporate governance practices.

The Corporate Governance and Management Discussion & Analysis Report, which form an integral part of this Report, are set out as "Annexure C" and "Annexure B", respectively together with the Certificate from the Secretarial Auditors of the Company regarding compliance with the requirements of Corporate Governance as stipulated in Listing Regulations.

Secretarial Standards

The Company complies with all applicable secretarial standards issued by the Institute of Company Secretaries of India.

Listing

The Companys Shares are listed on BSE Limited, Mumbai. The Company has paid Listing Fees for the year 2023-2024.

Depository services

The Companys Equity Shares have been admitted to the depository mechanism of the National Securities Depository Limited (NSDL) and also the Central Depository Services (India) Limited (CDSL). As a result, the investors have an option to hold the shares of the Company in dematerialized form in either of the two Depositories. The Company has been allotted ISIN No. INE292C01011.

Shareholders therefore are requested to take full benefit of the same and lodge their holdings with Depository Participants [DPs] with whom they have their Demat Accounts for getting their holdings in electronic form.

Internal control systems and their adequacy

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations. The scope and authority of the Internal Audit function is defined by the Audit Committee. To maintain its objectivity and independence, the Internal Audit function reports to the Chairman of the Audit Committee of the Board & to the Managing Director.

The Internal Audit monitors and evaluates the efficacy and adequacy of internal control system in the Company, its compliance with operating systems, accounting procedures and policies of the Company.

Based on the report of internal auditor, the Company undertakes corrective action in their respective areas and thereby strengthens the controls. Significant audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee of the Board.

Significant and material orders

There are no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and the Companys operations in future.

4. AUDIT AND AUDITORS

Statutory Auditor

M/s. Khurdia Jain & Co., Chartered Accountants, were appointed as Statutory Auditors of the Company at the 33rd Annual General Meeting (AGM) held on July 20, 2022 for a period of 5 years, to hold office from the conclusion of the 33rd Annual General Meeting till the conclusion of the 38th Annual General Meeting. However, they had tendered their resignation as Statutory Auditors of the Company w.e.f. July 31, 2023 resulting into a casual vacancy in the office of the Statutory Auditor of the Company as envisaged under Section 139(8) of the Companies Act, 2013.

The Board has in compliance of Section 139(8) of Companies Act, 2013 and rules there under, filled casual vacancy for financial year 2023-24 caused due to resignation of M/s. Khurdia Jain & Co., Chartered Accountants from position of Statutory Auditors of the Company by appointing M/s. Kothari Jain & Associates, Chartered Accountants, (FRN 113041W), as Statutory Auditors of the Company and subject to approval of Shareholders at ensuing Annual General Meeting.

In pursuance to the recommendation received from Audit Committee of the Company, the Board has also recommended appointment of M/s. Kothari Jain & Associates, Chartered Accountants, (FRN

113041W) as Statutory Auditors of the Company for period of 5 years from conclusion of 34th Annual General Meeting till the conclusion of 39th Annual General Meeting.

M/s. Kothari Jain & Associates, Chartered Accountants, (FRN 113041W) have submitted their consent to act as the Statutory Auditors of the Company along with their eligibility letter confirming that they are eligible for such appointment and have not been disqualified in any manner from being appointed as Statutory Auditors and their appointment meets the requirement of Section 141 of the Companies Act, 2013. The remuneration payable to the Statutory Auditor shall be determined by the Board of Directors based on the recommendation of the Audit Committee.

The Board recommends their appointment to the shareholders and agenda items for approval of members shall be included in the notice of the 34th AGM of the Company.

Report of the Statutory Auditor for the Financial Year 2022-2023:

M/s. Khurdia Jain & Co., Chartered Accountants, have submitted their Report on the Financial Statements of the Company for the FY 2022-2023, which forms part of the Annual Report. There are no observations (including any qualification, reservation, adverse remark or disclaimer) of the Auditors in the Audit Reports issued by them which call for any explanation from the Board of Directors.

Internal Auditor

Pursuant to the provisions of Section 138 of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014, the Board, on recommendation of the Audit Committee has appointed M/s. Pokharna and Associates, as internal auditors of the Company for the financial year 2023-2024.

Secretarial Auditor

M/s GMJ & Associates, Company Secretaries, were appointed as Secretarial Auditors of the Company for the financial year 2022-2023 pursuant to section 204 of the Act. The Secretarial Audit Report submitted by them in the prescribed form MR- 3 is attached as Annexure A to this report.

In addition to Secretarial Audit Report, M/s GMJ & Associates, Company Secretaries has issued the Secretarial Compliance Report under Regulation 24A of SEBI LODR Regulations, 2015 for the financial year 2022-2023.

There were no qualifications or observations or adverse remarks or disclaimer of the Secretarial Auditors in the Report issued by them for the financial year 2022-2023 which call for any explanation from the Board of Directors.

In terms of Section 204 of the Act, read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors, on the recommendation of the Audit Committee, have re-appointed M/s. GMJ & Associates, Company Secretaries as the Secretarial Auditors of the Company in relation to the financial year 2023-2024. The Company has received their written consent that the appointment is in accordance with the applicable provisions of the Act and rules framed there under.

Cost auditor:

The Board of Directors, on the recommendation of the Audit Committee, has appointed M/s. Poddar & Co., Cost Accountants as the Cost Auditors of the Company for the Financial Year 2023-2024 at a

remuneration of Rs.60,000/- (Rupees Sixty Thousand Only) plus applicable taxes and out of pocket expenses.

Pursuant to Section 148 of the Companies Act, 2013 read with Rule 14 of the Companies (Accounts) Rules, 2014, the remuneration payable for the year 2023-2024 to the Cost Auditors of the Company is subject to ratification by the shareholders at the ensuing Annual General Meeting. The remuneration to the Cost Auditors is commensurate with the size of the Company, work involved and scope of audit. Your directors recommend the same for approval by the Members at the ensuing Annual General meeting.

Cost records and audit

The Company has duly prepared and maintained the cost records of the business activities carried out by the Company during the financial year 2022-2023 as required pursuant to the provisions of section 148(1) of the Companies Act 2013 read with Companies (Cost Records and Audit) Rules 2014.

The Cost audit report for the financial year 2022-2023 has been filed with Central Government in the due course.

Reporting of frauds by auditor and other matters under Section 143(12) of the Act

During the year under review, the Statutory Auditors, Cost Auditors or Secretarial Auditors of the Company have not reported any frauds to the Audit Committee or to the Board of Directors under section 143(12) of the Act, including rules made there under.

5. HUMAN RESOURCE MANAGEMENT

Particulars of employees

The information required under Section 197(12) of the Act read with Rule 5(1), 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, including amendment thereto, is provided in the Annexure forming part of the Report. In terms of the second proviso to Section 136(1) of the Act, the Report and Accounts are being sent to the shareholders excluding the aforesaid Annexure. The said information is available for inspection by the members at the registered office of the Company during working hours on working days up to the date of the Annual General Meeting and if any member is interested in obtaining as copy thereof, such member may write to the Company Secretary and Compliance Officer at auro@aurolabs.com.

Prevention and prohibition of sexual harassment

The Company has in place a Policy on prohibition, prevention and redressal of sexual harassment of women at workplace and matters connected therewith or incidental thereto covering all the aspects as contained under “The Sexual Harassment of Women at Work Place (Prevention, Prohibition and Redressal) Act, 2013”. A copy of the same is available on the website of your Company at http://www.aurolabs.com/contact/Corporate Policies/Sexual%20harassment%20Policy.pdf

During the year, there were no complaints received relating to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

niiuuai twpui v ^

An Internal Complaint Committee has been set up with majority women. Committee has a full access to the Board of Directors and during the year under review, there were no reported instances pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

Health, Safety & Environment

The Company is committed to:

• Maintain an organizational culture of Health, Safety & Environmental excellence by conducting its business in a manner that will promote consistent development.

• Safe work, resource conservation, waste management and emergency response measures for continual improvement in performance.

• Design, construct, operate & maintain its facilities while assuring the best material and service quality and operate in a way that mitigates and minimizes risks and hazards.

• Prevention of ill-health, injuries and pollution by adopting best practices, carrying out periodic risk assessments, audits, reviews, inspections and providing awareness to employees and concerned stakeholders.

6. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNING AND OUTGO

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo pursuant to Section 134(3) (m) of the Companies Act, 2013, read with the Rule 8(3) of the Companies (Accounts) Rules, 2014 is given as under:

Conservation of energy:

1. the steps taken or impact on conservation of energy:

During the year, Company continued to focus on minimizing the energy consumption and the measures taken are summarised below:

a] Due consideration has been given to energy consumption while procuring equipments.

• As a responsible Corporate Citizen and in adherence to our climate change strategy, the Company is continuously taking effective steps to conserve energy and to reduce methane and other Green Houses Gases (GHG) emissions, wherever feasible.

• Except the emergency lights, all lights and electrical gadgets are turned off after working hours and on holidays at office premises of the Company to help in minimising the energy consumption.

b) Total energy consumption and under energy consumption per unit of the production as

Particulars

March 31, 2023 March 31, 2022

I. ELECTRICITY

a. Purchase Unit (in 000)

1779.63 1741.07

i. Total Amount (Rs. In 000)

17910.95 15411.94

ii. Rate / Unit (Rs.)

10.06 8.85

b. Own generation

NIL

NIL

(Through diesel Generator)

II. LIGHT DIESEL OIL LDO/ FURNACE OIL / BRIQUETTE

March 31, 2023 March 31, 2022

(For Production) Quantity (Ltr./kg. In 000)

a. LDO Litre

7.64 5.00

b. FURNACE OIL Litre

47.76 40.08

c. BRIQUETTES KG

2,325.23 2,201.62

Total Amount (Rs. In 000)

a. LDO

717.24 480.00

b. FURNACE OIL

3085.94 1,699.80

c. BRIQUETTES

23137.76 17,597.37

Average rate per Litre/KG (Rs.)

a. LDO Litre

93.88 96.00

b. FURNACE OIL Litre

64.61 42.41

c. BRIQUETTES KG

9.95 7.99

III. CONSUMPTION PER KG. OF PRODUCTION

a. Products (Kg.)

12,24,321 12,42,051

b. Electricity (Rs.)

14.63 12.41

c. Diesel / FO / Briquette (Rs.)

22.00 16.16

c) The steps taken by the Company for utilising alternate sources of energy: Not Applicable

d) The capital investment on energy conservation equipments: Not Applicable

Technology absorption

Technology absorption, adaptation and innovation: Not Applicable

i. the efforts made towards technology absorption during the year under review are:

ii. the benefits derived like product improvement, cost reduction, product development or import substitution:

iii. in case of imported technology (imported during the last three years reckoned from the beginning of the financial year):

a. the details of technology imported,

b. the Year of import

c. whether the technology been fully absorbed;

iv. During the year Company has incurred R&D Expenditure

Foreign exchange earnings and outgo:

The Foreign Exchange earned in terms of actual inflows during the year and the Foreign Exchange outgo during the year in terms of actual outflows:

(Rs. In 000)

Particulars

March 31, 2023 March 31, 2022

Foreign Exchange outgo

-CIF Value of Import:

250150.15 197560.76

-Foreign travelling expenses:

2742.97 11.42

Foreign Exchange earned

-FOB/CIF / CNF Value of export:

387859.26 371795.70

Business Responsibility Reporting

The Business Responsibility Reporting as required by Regulation 34(2) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, is not applicable to the Company for the financial year ending March 31, 2023.

7. RISK MANAGEMENT

Your Company recognizes that risk is an integral part of business and is committed to managing the risks in a proactive and efficient manner; your Company periodically assesses risks in the internal and external environment, along with the cost of treating risks and incorporates risk treatment plans in the strategy, business and operational plans.

The Company has in place a Risk Management Policy (a) to ensure that all the current and future material risk exposures of the Company are identified, assessed, quantified, appropriately mitigated, minimized and managed i.e. to ensure adequate systems for risk management. (b) to establish a framework for the companys risk management process and to ensure its implementation. (c) to enable compliance with appropriate regulations, wherever applicable, through the adoption of best practices (d) to assure business growth with financial stability. A copy of the same is available on the website of your Company at

http://www.aurolabs.com/contact/Corporate Policies/Risk%20Management%20Policy.pdf. There are no risks which threaten the existence of the Company.

8. QUALITY MANAGEMENT CERTIFICATION

The Company has also obtained various GMP Certifications.

APPRECIATION

Your directors would like to express their sincere appreciation to the companys Shareholders, Vendors including Banks, Government authorities, other business associates, who have extended their valuable sustained support and encouragement during the year under review. Your Directors also wish to place on record their appreciation for the hard work, solidarity, cooperation and support of employees at all levels.

For and on behalf of the Board of Directors
Auro Laboratories Limited

CIN No. L33125MH1989PLC051910

(Sharat Deorah)

Mumbai,

Chairman and Managing Director

August 23, 2023

DIN:00230784